Ubs Asset Management Americas Inc Corcept Therapeutics Inc Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 202,352 shares of CORT stock, worth $11.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
202,352
Previous 220,531 8.24%
Holding current value
$11.9 Million
Previous $7.17 Million 30.64%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$29.51 - $46.26 $536,462 - $840,960
-18,179 Reduced 8.24%
202,352 $9.36 Million
Q2 2024

Aug 13, 2024
BUY
$22.21 - $34.48 $2.2 Million - $3.41 Million
99,031 Added 81.51%
220,531 $7.17 Million
Q1 2024

May 15, 2024
SELL
$21.1 - $27.46 $73,850 - $96,110
-3,500 Reduced 2.8%
121,500 $3.06 Million
Q4 2023

Feb 14, 2024
BUY
$24.82 - $32.88 $104,566 - $138,523
4,213 Added 3.49%
125,000 $4.06 Million
Q3 2023

Nov 13, 2023
SELL
$21.97 - $33.8 $276,031 - $424,663
-12,564 Reduced 9.42%
120,787 $3.29 Million
Q1 2023

May 15, 2023
BUY
$19.2 - $24.47 $66,182 - $84,348
3,447 Added 2.65%
133,351 $2.89 Million
Q4 2022

Feb 14, 2023
SELL
$19.95 - $29.96 $60,987 - $91,587
-3,057 Reduced 2.3%
129,904 $2.64 Million
Q3 2022

Nov 14, 2022
SELL
$24.7 - $29.12 $765,378 - $902,341
-30,987 Reduced 18.9%
132,961 $3.41 Million
Q2 2022

Aug 12, 2022
SELL
$17.33 - $25.3 $73,912 - $107,904
-4,265 Reduced 2.54%
163,948 $3.9 Million
Q1 2022

May 16, 2022
BUY
$16.53 - $25.21 $307,705 - $469,284
18,615 Added 12.44%
168,213 $3.79 Million
Q4 2021

Feb 14, 2022
BUY
$17.1 - $23.34 $25,821 - $35,243
1,510 Added 1.02%
149,598 $2.96 Million
Q3 2021

Nov 15, 2021
BUY
$19.68 - $22.53 $201,779 - $231,000
10,253 Added 7.44%
148,088 $2.91 Million
Q2 2021

Aug 16, 2021
BUY
$19.97 - $24.43 $104,642 - $128,013
5,240 Added 3.95%
137,835 $3.03 Million
Q1 2021

May 14, 2021
SELL
$23.49 - $30.56 $227,618 - $296,126
-9,690 Reduced 6.81%
132,595 $3.15 Million
Q4 2020

Mar 01, 2021
BUY
$16.78 - $27.3 $554,813 - $902,647
33,064 Added 30.27%
142,285 $3.72 Million
Q3 2020

Nov 13, 2020
SELL
$12.46 - $19.98 $11,600 - $18,601
-931 Reduced 0.85%
109,221 $1.9 Million
Q2 2020

Aug 14, 2020
BUY
$11.0 - $18.26 $49,478 - $82,133
4,498 Added 4.26%
110,152 $1.85 Million
Q1 2020

May 15, 2020
BUY
$10.11 - $14.04 $270,270 - $375,331
26,733 Added 33.87%
105,654 $1.26 Million
Q4 2019

Feb 14, 2020
SELL
$12.06 - $16.96 $226,040 - $317,881
-18,743 Reduced 19.19%
78,921 $954,000
Q3 2019

Nov 14, 2019
BUY
$10.41 - $14.66 $253,629 - $357,176
24,364 Added 33.24%
97,664 $1.38 Million
Q2 2019

Aug 15, 2019
SELL
$9.78 - $12.76 $171,648 - $223,950
-17,551 Reduced 19.32%
73,300 $0
Q1 2019

May 14, 2019
BUY
$10.03 - $15.71 $112,777 - $176,643
11,244 Added 14.12%
90,851 $0
Q4 2018

Feb 13, 2019
BUY
$11.29 - $17.19 $136,597 - $207,981
12,099 Added 17.92%
79,607 $1.06 Million
Q3 2018

Nov 14, 2018
BUY
$12.27 - $15.65 $29,865 - $38,092
2,434 Added 3.74%
67,508 $0
Q2 2018

Aug 14, 2018
BUY
$15.3 - $19.69 $14,917 - $19,197
975 Added 1.52%
65,074 $0
Q1 2018

May 14, 2018
BUY
$14.59 - $25.5 $99,941 - $174,675
6,850 Added 11.97%
64,099 $0
Q4 2017

Feb 09, 2018
BUY
$15.77 - $20.72 $277,015 - $363,967
17,566 Added 44.27%
57,249 $0
Q3 2017

Nov 13, 2017
BUY
$12.3 - $19.3 $488,100 - $765,881
39,683
39,683 $0

Others Institutions Holding CORT

# of Institutions
349
Shares Held
86.1M
Call Options Held
1.12M
Put Options Held
667K
View Full List

About CORCEPT THERAPEUTICS INC

CORT Quotes by TradingView
  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $6.32B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email